Polycyclo Ring System Having The Additional Hetero Ring As One Of The Cyclos Patents (Class 514/210.21)
-
Patent number: 11931400Abstract: Therapeutic compositions and an associated method for improving a Toll-like receptor (TLR)-related condition, including determining a set of peptide sequences associated with a microorganism-related modulator of a TLR, determining a first set of binding parameters for the set of peptide sequences in relation to the TLR, selecting a target subset of peptide sequences from the set of peptide sequences based on the first set of binding parameters, reengineering the target subset of peptide sequences based on mutating amino acid residues of the target subset of peptide sequences, determining a second set of binding parameters for the reengineered target subset of peptide sequences in relation to the TLR, and identifying a first peptide for use in a therapeutic composition for improving the TLR-related condition, based on the second set of binding parameters for the reengineered target subset of peptide sequences.Type: GrantFiled: March 7, 2018Date of Patent: March 19, 2024Assignee: PSOMAGEN, INC.Inventors: Zachary Apte, Jessica Richman, Daniel Almonacid, Melissa Alegria, Valeria Marquez, Eduardo Morales, Rodrigo Ortiz, Janet Torres, Paulo Covarrubias, Javier Gimpel, Ingrid Araya
-
Patent number: 11919864Abstract: Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 or a MRGPR X2 ortholog dependent condition, more specifically, by contacting the MRGPR X2 or the MRGPR X2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.Type: GrantFiled: September 24, 2021Date of Patent: March 5, 2024Assignee: ESCIENT PHARMACEUTICALS, INC.Inventors: Marion Lanier, Marcus Boehm, Liming Huang, Esther Martinborough, Marcos Sainz, Brandon Selfridge, Adam Yeager
-
Patent number: 11890285Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a an agent that blocks Programmed Death-1 receptor (PD-1) and Programmed Death Ligand-1 (PD-L1) signaling and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, kits comprising the compositions and methods of use therefor.Type: GrantFiled: September 23, 2020Date of Patent: February 6, 2024Assignee: Mirati Therapeutics, Inc.Inventors: David Briere, James Gail Christensen, Peter Olson
-
Patent number: 11878976Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.Type: GrantFiled: March 3, 2022Date of Patent: January 23, 2024Assignee: ELI LILLY AND COMPANYInventors: Adedoyin David Abraham, Desta Doro Bume, Kevin Ronald Condroski, Robert Alan Hazlitt, Timothy Scott Kercher, Andrew Terrance Metcalf, Kaveri Balan Urkalan, Shane Michael Walls, Andrew Karl Dilger
-
Patent number: 11858915Abstract: Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: April 27, 2023Date of Patent: January 2, 2024Assignee: ORIC PHARMACEUTICALS, INC.Inventors: Chudi Ndubaku, Jared Thomas Moore, Paul Anthony Gibbons, Jae Hyuk Chang, F. Anthony Romero, Xiaohui Du, Hiroyuki Kawai, Stephane Ciblat, Hong Wang, Vincent Albert, Lea Constantineau-Forget, Hugo De Almeida Silva, Dilan Emine Polat, Amit Nayyar, Daniel Gordon Michael Shore, Kejia Wu, Joanne Tan
-
Patent number: 11819499Abstract: Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.Type: GrantFiled: July 26, 2022Date of Patent: November 21, 2023Assignee: BioSplice Therapeutics, Inc.Inventor: Luis A. Dellamary
-
Patent number: 11807650Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.Type: GrantFiled: January 27, 2022Date of Patent: November 7, 2023Assignee: Novartis AGInventors: David R. Anderson, Robert Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
-
Patent number: 11767312Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.Type: GrantFiled: April 5, 2023Date of Patent: September 26, 2023Assignee: GENENTECH, INC.Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
-
Patent number: 11713321Abstract: Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein, A, X, Y, R1, R2, R3, R4 and R5 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of the NLRP3 inflammasome are also provided.Type: GrantFiled: September 14, 2021Date of Patent: August 1, 2023Assignee: HALIA THERAPEUTICS, INC.Inventors: David James Bearss, John Sai Keong Kauwe, III, Alexis Henri Abel Mollard
-
Patent number: 11708352Abstract: This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.Type: GrantFiled: October 15, 2021Date of Patent: July 25, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Csaba J. Peto, David Jablons, Hassan Lemjabbar-Alaoui
-
Patent number: 11691963Abstract: The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.Type: GrantFiled: May 5, 2021Date of Patent: July 4, 2023Assignee: Ajax Therapeutics, Inc.Inventors: Craig E. Masse, Jeremy R. Greenwood, Sayan Mondal, Jiayi Xu, Phani Ghanakota, Fiona Michelle McRobb, Nicholas Boyles
-
Patent number: 11672800Abstract: The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.Type: GrantFiled: April 20, 2018Date of Patent: June 13, 2023Assignee: Epizyme, Inc.Inventors: John Emmerson Campbell, Kenneth William Duncan, Maria Alejandra Raimondi, Christine Klaus, Elayne Penebre
-
Patent number: 11667611Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.Type: GrantFiled: May 6, 2019Date of Patent: June 6, 2023Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ankush Argade, Arvinder Sran, David Carroll, Jeffrey Clough, Kin Tso, Somasekhar Bhamidipati, Sambaiah Thota, Rajinder Singh, Vanessa Taylor, Hui Li, Esteban Masuda
-
Patent number: 11608335Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: February 11, 2019Date of Patent: March 21, 2023Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Jian Zhao, Shimiao Wang, Yunfei Zhu
-
Patent number: 11596632Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating gastrointestinal diseases or disorders such as ulcerative colitis.Type: GrantFiled: December 19, 2019Date of Patent: March 7, 2023Assignee: Incyte CorporationInventors: Krishnaswamy Yeleswaram, Paul Smith, Gregory F. Hollis
-
Patent number: 11524957Abstract: The present invention provides processes and synthetic intermediates for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4 {3H)-one or a salt, hydrate, or tautomer thereof, or any combination thereof, which are Cdc7 kinase inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with Cdc7 activity.Type: GrantFiled: April 1, 2019Date of Patent: December 13, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Lei Zhu, John Daniel Bailey, Landon Durak, Joshua David Waetzig, Masahiro Mizuno, Kazuhiro Maeda, Tsuneo Yasuma, Hiroshi Yamaguchi, Koichiro Fukuoka, Kazuyuki Akiyama
-
Patent number: 11512090Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.Type: GrantFiled: June 10, 2019Date of Patent: November 29, 2022Assignee: Pipeline Therapeutics, Inc.Inventors: Yifeng Xiong, Thomas Schrader, Austin Chen, Jeffrey Roger Roppe, Jill Melissa Baccei, Yalda Bravo
-
Patent number: 11512072Abstract: The present disclosure provides azetidine compounds of Formula I and their pharmaceutically acceptable salts, their compositions, and methods for their use in determining azetidine compound binding to proteins. The azetidine compounds are useful as probes, for monitoring diacylglycerol kinase activity, and for identifying druggable targets.Type: GrantFiled: April 19, 2019Date of Patent: November 29, 2022Assignee: University of Virginia Patent FoundationInventors: Ku-Lung Hsu, Rebecca L. McCloud
-
Patent number: 11498920Abstract: Novel 4-(1H-imidazol-5-yl)-1H-pyrrolo[2,3-b]pyridine compounds that are useful in the treatment of lymphomas, leukaemias, and solid tumors.Type: GrantFiled: March 26, 2019Date of Patent: November 15, 2022Assignee: MASARYKOVA UNIVERZITAInventors: Vitezslav Bryja, Pavlina Janovska, Michaela Gregorova, Vaclav Nemec, Prashant Khirsariya, Kamil Paruch
-
Patent number: 11459327Abstract: Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and the use thereof are described. Compounds of the present invention have a structure represented by formula (I). Further disclosed are preparation methods for said compounds, and the use of said compounds as KRASG12C inhibitors. The compounds have an excellent ability to selectively inhibit KRASG12C, improved pharmacodynamic and pharmacokinetic performance, and reduced toxic side effects.Type: GrantFiled: June 7, 2021Date of Patent: October 4, 2022Assignees: Suzhou Zelgen Biopharmaceuticals Co., Ltd., Shanghai Zelgen Pharma.Tech Co., Ltd.Inventors: Binhua Lv, Dawei Cui, Lianjun Liu, Tao Han, Runqing Wang, Peizhong Ni, Zelin Sheng
-
Patent number: 11459337Abstract: Disclosed in the present invention are an IRAK4 inhibitor, and an application thereof in preparation of a drug for treating IRAK4-related diseases. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 25, 2019Date of Patent: October 4, 2022Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Inc.Inventors: Yang Zhang, Jianfei Wang, Haizhong Tan, Jie Li, Jian Li, Shuhui Chen
-
Patent number: 11458123Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.Type: GrantFiled: November 1, 2017Date of Patent: October 4, 2022Assignee: ARVINAS OPERATIONS, INC.Inventors: Andrew P. Crew, Michael Berlin, Hanqing Dong, Alexey Ishchenko
-
Patent number: 11446288Abstract: Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.Type: GrantFiled: July 27, 2020Date of Patent: September 20, 2022Assignee: BioSplice Therapeutics, Inc.Inventor: Luis A. Dellamary
-
Patent number: 11390617Abstract: Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with rituximab, for treating, preventing or managing non-Hodgkin lymphoma.Type: GrantFiled: April 9, 2020Date of Patent: July 19, 2022Assignee: CELGENE CORPORATIONInventors: Maria Soraya Carrancio Anton, Tonia J. Buchholz, Antonia Lopez-Girona, Rama Krishna Narla, Michael Pourdehnad
-
Patent number: 11390632Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.Type: GrantFiled: March 19, 2020Date of Patent: July 19, 2022Assignee: Hoffmann-La Roche Inc.Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfleger, Christian Moessner
-
Patent number: 11365250Abstract: The present disclosure generally relates to compositions and methods for cancer immunotherapy, as well as hematopoietic recovery following cancer treatment such as chemotherapy or irradiation.Type: GrantFiled: November 29, 2018Date of Patent: June 21, 2022Assignee: The Board of Regents of The University of Texas SystemInventors: Bruce Beutler, Evan Nair-Gill, Xue Zhong, Jinglei Zhang, Pingping Wang
-
Patent number: 11358952Abstract: Provided herein are 4-aminoisoindoline-1,3-dione compounds having the following structure: wherein R, Ring A, and n are as defined herein, compositions comprising an effective amount of a 4-aminoisoindoline-1,3-dione compound, and methods for treating or preventing disorders.Type: GrantFiled: April 22, 2019Date of Patent: June 14, 2022Assignee: Celgene CorporationInventors: Matthew D. Alexander, Soraya Carranclo, Matthew D. Correa, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, Dehua Huang, Timothy S. Kercher, Antonia Lopez-Girona, Mark A. Nagy, Veronique Plantevin-Krenitsky
-
Patent number: 11352353Abstract: A heterocyclic compound which is an inhibitor of FGFR4 (fibroblast growth factor receptor 4) is described. Specifically, a compound represented by the following formula (I), including an isomer (enantiomer or diastereomer) which may be present, or a pharmaceutically acceptable salt thereof, prodrugs, deuterated derivatives, hydrates, solvates, are described. The definition of each group in the formula (I) is as described in the specification. The compounds have FGFR4 inhibitory activity and can be used for the prevention or treatment of diseases associated with FGFR4 activity or expression, and can also be used in combination with other drugs for the treatment of various related diseases, as described.Type: GrantFiled: May 27, 2017Date of Patent: June 7, 2022Assignee: Hangzhou Innogate Pharma Co., Ltd.Inventors: Hancheng Zhang, Shifeng Liu, Xiangyang Ye
-
Patent number: 11339162Abstract: Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as cancer.Type: GrantFiled: December 20, 2021Date of Patent: May 24, 2022Assignee: Recurium IP Holdings, LLCInventors: Guobao Zhang, Peter Qinhua Huang, Kevin Duane Bunker, Sayee Gajanan Hegde
-
Patent number: 11319295Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: (Formula (I)). Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.Type: GrantFiled: October 4, 2018Date of Patent: May 3, 2022Assignee: MERCK SHARP & DOHME CORP.Inventors: Catherine M. White, Meredeth Ann McGowan, Yongxin Han, Nunzio Sciammetta
-
Patent number: 11306069Abstract: Novel benzimidazole enantiomeric derivatives, their process of preparation and their therapeutical uses as dual H1 and H4 receptor ligands are disclosed.Type: GrantFiled: November 15, 2018Date of Patent: April 19, 2022Assignee: BIOPROJETInventors: Isabelle Berrebi-Bertrand, Xavier Billot, Thierry Calmels, Marc Capet, Stéphane Krief, Olivier Labeeuw, Jeanne-Marie Lecomte, Nicolas Levoin, Xavier Ligneau, Philippe Robert, Jean-Charles Schwartz
-
Patent number: 11306093Abstract: A process for preparing the compound of formula I comprising: a) coupling a compound of formula 2 wherein a leaving group O—SO2—R is selected from the triflate group, the tosylate group, the mesylate group, the besylate group, the nosylate group or the brosylate group, with a suitable boronic acid, a trifluoroborate or a boronic acid ester under argon condition and in the presence of a catalyst and a base in a suitable solvent and then isolating the product as an acid addition salt to afford the compound of formula Ia and b) converting the acid addition salt of formula Ia wherein the acid HX comprises suitable organic or inorganic acids into the compound of formula I by treatment with at least a stoichiometric equivalent of a suitable base.Type: GrantFiled: March 6, 2019Date of Patent: April 19, 2022Assignee: Hoffmann-La Roche, Inc.Inventors: Bjoern Bartels, Philipp Cueni, Matthias Koerner, Dieter Muri
-
Patent number: 11279702Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.Type: GrantFiled: October 15, 2021Date of Patent: March 22, 2022Assignee: KALLYOPE, INC.Inventors: Iyassu Sebhat, Shuwen He
-
Patent number: 11274107Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.Type: GrantFiled: December 22, 2017Date of Patent: March 15, 2022Assignee: Cadent Therapeutics, Inc.Inventors: David R. Anderson, Robert A. Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
-
Patent number: 11267806Abstract: The present invention relates to an indazole compound for use in inhibiting kinase activity, and relates to a preparation and use thereof. Specifically disclosed in the present invention is an indazole compound represented by formula (I), or a crystal form, a prodrug, a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a solvate or a hydrate thereof, or a pharmaceutical composition thereof. The compound of the present invention and the composition containing the compound have an excellent inhibitory effect on kinase proteins, and have better pharmacokinetic parameter characteristics, may increase the drug concentration of the compound in an animal, and improve the efficacy and safety of the drug.Type: GrantFiled: June 25, 2018Date of Patent: March 8, 2022Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Huanyin Li
-
Patent number: 11254669Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.Type: GrantFiled: November 11, 2019Date of Patent: February 22, 2022Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden
-
Patent number: 11254668Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.Type: GrantFiled: August 9, 2018Date of Patent: February 22, 2022Assignee: Pfizer Inc.Inventors: Brian Stephen Gerstenberger, Andrew Fensome, Dafydd Rhys Owen, Matthew Frank Brown, Matthew Merrill Hayward, Felix Vajdos, Li Huang Xing, Stephen Wayne Wright
-
Patent number: 11247990Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X1, X2, X3, R1, R2 and R3 are as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor.Type: GrantFiled: December 5, 2018Date of Patent: February 15, 2022Assignee: ARRAY BIOPHARMA INCInventors: Shelley Allen, Mark Laurence Boys, Adam Cook, John Gaudino, Ronald Jay Hinklin, Ellen Laird, Oren T. McNulty, Andrew T. Metcalf, Brad Newhouse, John E. Robinson
-
Patent number: 11248007Abstract: Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-?B signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.Type: GrantFiled: March 8, 2018Date of Patent: February 15, 2022Assignees: Cornell University, Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, David A. Scott, John Hatcher, Ari M. Melnick, Lorena Fontan Gabas
-
Patent number: 11234976Abstract: Described herein are methods for using compounds that activate pyruvate kinase.Type: GrantFiled: June 10, 2016Date of Patent: February 1, 2022Assignee: Agios Pharmaceuticals, Inc.Inventors: Samuel V. Agresta, Yue Chen, Marvin B. Cohen, Lenny Dang, Charles Kung, Elizabeth A. Merica, Bruce A. Silver, Hua Yang
-
Patent number: 11229649Abstract: Methods for treating or prophylaxis of a cryptosporidium infection using compositions comprising a structure disclosed herein. Also provided are pharmaceutical compositions and kits for alleviating the symptoms of, for treating, or for preventing the occurrence of cryptosporidium infection. The kits comprise one or more compounds having a structure disclosed herein, such as in an oral composition, and instructions for use, storage, and the like.Type: GrantFiled: July 29, 2019Date of Patent: January 25, 2022Assignee: University of Vermont and State Agricultural CollegeInventors: Christopher D. Huston, Kovi Bessoff, Rajiv Satish Jumani
-
Patent number: 11220496Abstract: Compounds and embodiments of a method for treating and/or preventing autoimmune diseases are disclosed. The method includes administering to a subject having an autoimmune disease, such as an inflammatory bowel disease, a therapeutically effective amount of a compound according to formula I wherein X and Y independently are O or NR1; each R1 is independently H or C1-C6 alkyl; ring A is aryl; each R2 independently is H, alkyl, alkoxy, amide, cyano, halo, haloalkyl, hydroxyalkyl, heteroalkyl, heterocyclyl, sulfonyl, sulfonamide, or two R2 groups, taken together with the atom or atoms to which they are attached, combine to form a 4-10 membered ring system; p is 0, 1, 2, 3, or 4; R3 and R4 independently are H or C1-C6 alkyl; and R5 is halo, cyano, or C1-C6 alkyl.Type: GrantFiled: August 26, 2019Date of Patent: January 11, 2022Assignee: Rigel Pharmaceuticals, Inc.Inventors: Esteban Masuda, Rajinder Singh, Vanessa Taylor, Donald G. Payan
-
Patent number: 11214573Abstract: The present invention provides azetidinyl phenyl, pyridyl, or pyrazinyl carboxamide derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAKs) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.Type: GrantFiled: November 13, 2019Date of Patent: January 4, 2022Assignees: Incyte Holdings Corporation, Incyte CorporationInventors: Wenqing Yao, David M. Burns, Jincong Zhuo
-
Patent number: 11180501Abstract: Disclosed in the present disclosure are a crystal form of a ?-lactamase inhibitor and a preparation method therefor, as well as an application of the crystal form in preparing a ?-lactamase inhibitor drug.Type: GrantFiled: December 3, 2018Date of Patent: November 23, 2021Assignee: QILU PHARMACEUTICAL CO., LTD.Inventors: Cheng Li, Zhigang Huang, Charles Z. Ding, Weidong Li
-
Patent number: 11174232Abstract: The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.Type: GrantFiled: May 6, 2020Date of Patent: November 16, 2021Assignee: Aurigene Discovery Technologies LimitedInventors: Susanta Samajdar, Ramulu Poddutoori, Chetan Pandit, Subhendu Mukherjee, Rajeev Goswami
-
Patent number: 11174251Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.Type: GrantFiled: October 17, 2019Date of Patent: November 16, 2021Assignee: Rigel Pharmaceuticals, Inc.Inventors: Hui Li, Thilo J. Heckrodt, Yan Chen, Darren John McMurtrie, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
-
Patent number: 11161852Abstract: Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein, A, X, Y, R1, R2, R3, R4 and R5 are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of the NLRP3 inflammasome are also provided.Type: GrantFiled: May 7, 2021Date of Patent: November 2, 2021Assignee: HALIA THERAPEUTICS, INC.Inventors: David James Bearss, John Sai Keong Kauwe, III, Alexis Henri Abel Mollard
-
Patent number: 11154539Abstract: The invention provides a compound for use in the treatment of T-Cell Acute Lymphoblastic Leukaemia (T-ALL), the compound having the formula (1): or being a pharmaceutically acceptable salt thereof; wherein: n is 0, 1 or 2; Ar1 is selected from an optionally substituted phenyl, pyridyl, thienyl and furanyl; Q1 is selected from C(?O), S(?O) and SO2; A is absent or is NR2; R1 is selected from: hydrogen; an optionally substituted C1-6 non-aromatic hydrocarbon group; and optionally substituted 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings; R2 is selected from hydrogen and C1-4 alkyl; or NR1R2 forms an optionally substituted 4- to 7-membered non-aromatic nitrogen-containing heterocyclic ring optionally containing a second heteType: GrantFiled: October 20, 2017Date of Patent: October 26, 2021Assignee: Sareum LimitedInventor: John Charles Reader
-
Patent number: 11155879Abstract: The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.Type: GrantFiled: March 1, 2017Date of Patent: October 26, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Akihiro Ohashi, Kenichi Iwai, Tadahiro Nambu, Ryo Dairiki, Yuko Ishii
-
Patent number: 11149025Abstract: This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.Type: GrantFiled: February 13, 2020Date of Patent: October 19, 2021Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Csaba J. Peto, David Jablons, Hassan Lemjabbar-Alaoui